**Call text**

Third transnational call for research projects within the JPIAMR

# To unravel the dynamics of transmission and selection of antimicrobial resistance (AMR) at the genetic, bacterial, animal, human, societal, and environmental levels, in order to design and evaluate preventive and intervening measures for controlling resistance.

## 1. Aim of the call:

The primary aim of the third joint call of JPIAMR is to combine the resources, infrastructures, and research strengths of multiple countries in order to address transmission of antibiotic resistance following a 'One Health Approach'. The goal is to foster multinational research collaborations to add value to and to build upon the research conducted independently at national level and to work together to improve the control of resistant bacterial infections of clinical and/or veterinary importance only.

An organism develops resistance to a drug either by a gene mutation or by the acquisition of genetic components from another strain (i.e. transmission of resistance). Resistant organisms can multiply in the presence of a drug (i.e. selection of resistance traits) but without transmission, resistance would remain an isolated problem.

To understand the complex biological and environmental interactions that shape the spread of antibiotic resistance, we must identify and characterise the determinants that contribute to the spread of resistance in and between different reservoirs; including humans (sick and healthy people), animals (livestock, companion and wild animals) and the environment (indoor and outdoor).

Investigating the complex biology and epidemiology of selection and transmission of resistance is crucial in order to design preventive measures to address this public threat. The success and abundance of antibiotic resistant bacterial strains with particular public health importance should be determined through the development of risk assessment approaches that are based on the genomic repertoire of bacterial pathogens and the ecological constraints that determine their fitness in clinical, community, veterinary, and environmental settings.

We expect that most collaborations will be multidisciplinary with expertise that could include, but are not limited to, bacteriologists (clinical, veterinary, and environmental), chemists, ecologists, mathematicians, informatics and computational modellers, medical practitioners (human and veterinary), etc., where appropriate. Consortia are encouraged to include participants from academia, medical and public health practitioners (both human and veterinary), policy makers, and industry, where appropriate (please note the national/regional regulations).

**Only multinational projects will be funded. Each proposal must involve a minimum of three (3) countries participating in this call and a maximum of six (6) project participants** (see 2.1 Eligibility criteria for further details).

Submissions of proposals will be in two steps: The deadline for submitting pre-proposals is **March 21st, 2016** and invited full proposals must be submitted by **July 4th, 2016**. Projects will be expected to start at the **end of 2016 or beginning of 2017**. Funding will be granted for a maximum of three years.

## 1.1 Call Topic:

- To understand the acquisition, persistence/ retention, and transmission of resistant organisms and resistance genes, research should investigate:
    - Selection of resistance and its transmission between individuals and between human and non-human sources
    - The success of clones, organisms, and resistance patterns and the role of different genetic elements.
    - The fitness of the resistant bacteria in clinical, community, veterinary, and environmental settings.

- In order to identify and target better prevention measures and management practices to control resistance, research in the following areas are needed:
    - Quantitative multilevel modelling to understand the dissemination of AMR between different environments (here the "environment" is seen in its broadest sense from the host to man-made settings and natural environments)
    - Risk assessment studies to estimate which transmission pathways from the environment (indoor and outdoor) and/or animals to humans are the most important to control in order to minimise the transfer of resistant organisms.
    - Explore potential interventions and mitigation strategies, including new strategies, which minimise the emergence, transmission, and/or exposure risk of resistance in clinical, veterinary, community and environmental settings in a cost-effective, sustainable way.

Proposals submitted may include, but are not limited to, the following types of research:

- Multidisciplinary studies investigating the molecular mechanisms that lead to the emergence, acquisition, persistence/ retention, and transmission of AMR
- Development or use of appropriate animal models to study the selection and transmission of AMR within the host.
- Investigation of specific drivers of the emergence, evolution and co-selection of resistance; e.g. optimisation of dosing strategies to minimise impact on gut microbiota and selection for AMR
- Understanding how resistance genes are transferred within the microbiome (including the gut, skin, respiratory and oral microbiomes), and between pathogenic and commensal bacteria, in both humans and animals.
- Investigating the role of the host immune response in selection and transmission of resistance bacteria.

- How do resistance bacteria and/or resistance genes in the environment (e.g. soil, feed, wastewater, freshwater, air, novel reservoirs) impact humans?
- What is the causality and directionality of spread of resistance genes between human and animal reservoirs?
- How does the frequency and duration of hospital admission and the volume of patient traffic between healthcare institutions contribute to dissemination of AMR between human and non-human reservoirs, and between humans, at both the individual and the population level?
- How does the transport of farm animals and the complex dynamics of the modern food chain contribute to dissemination of AMR between human and non-human reservoirs, between individuals, and on the population level?
- Exposure assessment of humans to indoor and outdoor environment and the role of various transmission pathways to colonization of AMR.
- What are critical control points at which interventions could substantially affect the spread of resistance? What are the most cost-effective prevention measures to reduce the transmission of resistance genes between human and non-human reservoirs, and between regional, national and international patient networks?
- What is the impact of human activities on the spread of antimicrobial agents, resistance genes, and multi-drug-resistant bacteria to water (both potable, and water in the environment), food and soils, and how can bio-remediative and bio-restorative interventions (waste management techniques) reduce the emergence and spread of AMR?

**Following sub-topics are not in the purpose of the call:**

- Development of new antimicrobial drugs that select less for resistance or block transmission
- Development or testing of diagnostic tools to monitor selection or transmission of AMR

## 1.2 Expected Impact:

It is expected that through international collaborations that combine complementary and synergistic research strengths, this JPIAMR call will increase the understanding of AMR transmission and facilitate the generation and application of new approaches to prevent and/or overcome antibiotic resistance. Proposals are expected to clearly define targets and milestones to deliver clinically relevant outcomes within the funding period.

## 2. Application:

### 2.1 Eligibility

Applicants must adhere to the specific regulations of the national funding organisations. Each transnational consortium submitting a proposal must involve:

- a minimum of three (3) eligible partners from three (3) different countries participating in the call
- a maximum of six (6) project participants
- a maximum of two (2) project participants funded by the same funding organisation.
- Project participants not eligible to be funded (e.g. from non-funding countries or not fundable according to national/regional regulations of the participating funding countries) may be involved in projects if they secure their own funding and if their expertise is indispensable for reaching the objectives. However, the maximum number of six participants may not be exceeded, unless partners from under-represented countries are included (see below). The consortia should always consist of a majority of funded project participants.
- Project participants not eligible to be funded cannot be consortium coordinators and must accept all JPIAMR rules and guidelines just as funded members.
- Consortia including partners from countries that are to date underrepresented in the JPIAMR funding scheme may increase the total number of partners to 7. (The underrepresented countries are Poland, and Latvia.

### 2.2 Submission of joint transnational proposal

Submissions of proposals will be in two steps. In both cases, one joint proposal document (in English, and following the provided template) shall be prepared by the project participants of a joint transnational proposal, and must be submitted to the Joint Call Secretariat by the coordinator. A submission tool will be implemented in the JPIAMR website (http://www.jpiamr.eu/activities/joint-calls/3rd-joint-call-transmission-dynamics/). For details see also the **Guidelines for Applicants.**

The two-steps application process (pre-proposal, full proposal) will have the following timetable:

| | |
|---|---|
| January 18th, 2016 | **Publication of the JPIAMR ERA-NET Co-funded Call** |
| March 21st, 2016 (17:00 CET) | **Submission deadline for pre-proposals** |
| Mid May 2016 | **Full proposal invitations send to project coordinators** |
| July 4th, 2016 (17:00 CET) | **Submission deadline for full proposals** |
| By October 15th, 2016 | **Final funding decision to applicants** |
| End of 2016/Early 2017 | **Start of funding** |

## 2.3 Financial modalities and funding prerequisites

Funding is granted for a maximum of three years in accordance with national regulations. **Applicants must refer and adhere to their own specific national regulations and scientific remits as detailed in the National and Regional Requirements (see Annex B).**

The funds provided by the Parties are listed in the table below. The "virtual common pot model" shall apply for this transnational call. As such, each country will fund its own approved project partners. The proposals will be funded following the ranking list recommended by the Peer Review Panel.

### Anticipated funding provided by each party

| ***Country*** | ***Name of Organisation*** | | ***Contribution in million €*** |
|---|---|---|---|
| Belgium | Fonds National de la Research Scientifique | FRS-FNRS | 0,2M€ |
| Belgium | Fonds voor Wetenschappelijk Onderzoek-Vlaanderen | FWO | 0,2M€ |
| Canada | Canadian Institutes of Health Research | CIHR | $3.6M CAD |
| Denmark | Innovationsfonden | DIF | 1M€ |
| France | The French National Research Agency | ANR | 2M€ |
| Germany | Bundesministerium für Bildung und Forschung (BMBF) / Deutsches Zentrum für Luft- und Raumfahrt (DLR) | BMBF/DLR | 3M€ |
| Israel | Chief Scientist Office, Ministry of Health | CSO-MOH | 0,2M€ |
| Italy | Ministry of Health | IT-MOH | 0,8M€ |
| Latvia | Valsts izglītības attīstības aģentūra | VIAA | 0,2M€ |
| Netherlands | Zorgonderzoek Nederland | ZON | 1M€ |
| Norway | The Research Council of Norway | RCN | 2M€ |
| Poland | Narodowe Centrum Nauki | NCN | 0,25M€ |
| Portugal | Fundação para a Ciência e a Tecnologia | FCT | 0,4M€ |
| Romania | National Authority for Scientific Research and Innovation | ANCSI | 0.5 M€ |
| Spain | National Institue of Health Carlos III | ISCIII | 0,5M€ |
| Spain | Ministerio de Economia y Competitividad | MINECO | 0,5M€ |
| Sweden | Swedish Research Council | SRC | 4M€ |
| Sweden | Forskningsrådet för miljö, areella näringar och samhällsbyggande | Formas | 1M€ |
| Switzerland | Swiss National Science Foundation | SNSF | 0,6M€ |
| Turkey | Turkiye bilimsel ve teknolojik arastirma kurumij | Tubitak | 0,8M€ |
| UK | Medical Research Council | MRC | 3M€ (£2.16M) |

Each funded consortium should provide a consortium agreement (CA) signed by all participants. The project consortium is strongly encouraged to sign this CA before the start of the project to clarify the potential IPR matters (such as licensing in, licensing out, patent and exploitation strategy), and in any case no later than six months after the official project start date. The points that must be addressed in the CA are detailed in the Annex C.

## 2.4 Contact persons

The only official communication line of the proposal is between the Joint Call Secretariat and the project coordinator. The project coordinator will be the person contacted by the Joint Call Secretariat during the application procedure, so he/she must forward this information to the other participants. Each funding organization has national contact persons who can be contacted for information about the specific national requirements (see Annex A).

Please note that country specific requirements might apply to this call. Compliance with the national/regional regulations specified in the country specific information is mandatory (See Annex B). We strongly advise you to contact your national/regional representative prior to submitting a pre-proposal.

# 3 Evaluation

Pre-proposals and full proposals will be assessed according to specific evaluation criteria (see below), using a common evaluation form. A scoring system from 0 to 5 will be used to evaluate the proposal's performance with respect to the different evaluation criteria.

**Scoring system:**

**0: Failure.** The proposal fails to address the criterion in question, or cannot be judged because of missing or incomplete information.

**1: Poor.** The proposal shows serious weaknesses in relation to the criterion in question.

**2: Fair.** The proposal generally addresses the criterion, but there are significant weaknesses that need corrections.

**3: Good.** The proposal addresses the criterion in question well but certain improvements are necessary.

**4: Very good.** The proposal addresses the criterion very well, but small improvements are possible.

**5: Excellent.** The proposal successfully addresses all aspects of the criterion in question.

**Evaluation criteria:**

1. Excellence
    a. Clarity and pertinence of the objectives
    b. Credibility of the proposed approach and methodology
    c. Soundness of the concept
    d. Innovative potential
    e. Competence and experience of participating research partners in the field(s) of the proposal (previous work in the field, specific technical expertise)
2. Impact

a. Potential of the expected results for future clinical, public health and/or other socio-economic health relevant applications including patients' needs
b. Added-value of transnational collaboration: gathering a critical mass of patients/biological material, sharing of resources (models, databases, diagnosis etc.), harmonization of data, sharing of specific know-how and/or innovative technologies.
c. Effectiveness of the proposed measures to exploit and disseminate the project results (including management of IPR), to communicate the project, and to manage research data where relevant
d. Industry and Patient Organization participation/engagement (when appropriate/applicable)

3. Quality and efficiency of the implementation
    a. Coherence and effectiveness of the work plan, including appropriateness of the allocation of tasks, resources and time-frame
    b. Complementarity of the participants within the consortium
    c. Appropriateness of the management structures and procedures, including risk and innovation management
    d. Concept for sustainability of infrastructures initiated by the project
    e. Budget and cost-effectiveness of the project (rational distribution of resources in relation to project's activities, partners responsibilities and time frame)

**Sub-criteria 2a and 2b will be prioritized for assessing the impact of proposals (pre- and full proposal stage).**

Evaluation scores will be awarded for the 3 main criteria, and not singularly for the different aspects listed below the criteria. The threshold for individual criteria will be 3. The maximum score that can be reached from all three criteria together is 15 points.

**Annex A: National contact persons for each party providing funding**

| *Country* | *Funding org.* | *Contact person(s)* | *Email* |
|---|---|---|---|
| Belgium | FRS-FNRS | Arnaud Goolaerts | arnaud.goolaerts@frs-fnrs.be |
| Belgium | FWO | Olivier Boehme | eranet@fwo.be |
| Canada | CIHR | Olivier Jacob-Gravel<br>Élisabeth Pagé | olivier.jacob-gravel@cihr-irsc.gc.ca<br>elisabeth.page@crchudequebec.ulaval.ca |
| Denmark | DIF | Stine Larsen | stine.larsen@innofond.dk |
| France | ANR | Amélie Vergne<br>Martine Batoux | JPI-AMRCalls@agencerecherche.fr |
| Germany | BMBF/DLR | Dr. Barbara Junker<br>Dr. Martin Barth | barbara.junker@dlr.de<br>M.Barth@dlr.de |
| Israel | CSO-MOH | Ahmi Ben-Yehudah | ahmi.by@moh.gov.il |
| Italy | IT-MOH | Dr. Raffaele Ruocco | r.ruocco@sanita.it |
| Latvia | VIAA | Dr Maija Bundule<br>Dr Uldis Berkis | Maija.Bundule@viaa.gov.lv<br>Uldis.Berkis@viaa.gov.lv |
| Netherlands | ZON | Thera Habben Jansen | HabbenJansen@zonmw.nl |
| Norway | RCN | Sonja Prehn<br>Dyveke Hetland | sp@rcn.no<br>dhe@rcn.no |
| Poland | NCN | Jerzy Fraczek<br>Malwina Gębalska, | jerzy.fraczek@ncn.gov.pl<br>malwina.gebalska@ncn.gov.pl |
| Portugal | FCT | Marta Abrantes<br>Anabela Isidro | marta.abrantes@fct.pt<br>anabela.isidro@fct.pt |
| Romania | ANCSI | Ioana Ispas | Ioana.ispas@ancs.ro |
| Spain | ISCIII | Irene Sánchez | Isanchezgarcia@isciii.es |
| Spain | MINECO | Estrella Fernandez | amr@mineco.es |
| Sweden | SRC | Anh Thu Nguyen Hoang<br>Patriq Fagerstedt | anhthu.nguyenhoang@vr.se<br>patriq.fagerstedt@vr.se |
| Sweden | Formas | Mattias Norrby | mattias.norrby@formas.se |
| Switzerland | SNSF | Barbara Flückiger | barbara.flueckiger@snf.ch |
| Turkey | Tubitak | Burak Barut<br>Emine Derebay | burak.barut@tubitak.gov.tr<br>emine.derebay@tubitak.gov.tr |
| UK | MRC | Ruth Kelly<br>Ghada Zoubiane | amr@headoffice.mrc.ac.uk |

## Annex B: Specific National and Regional Requirements

### Belgium – FRS-FNRS

| | |
|---|---|
| **Funding of industrial partners eligible?** | No |
| **Participation of industry required?** | No |
| **Maximum funding** | 200.000 EUR/1 Project/3yrs |
| **Eligible costs** | See national regulations (http://www.ncp.frs-fnrs.be/index.php/appels/era-nets) |
| **Additional documents required** | No |
| **Other national restrictions** | See national regulations (http://www.ncp.frs-fnrs.be/index.php/appels/era-nets) |

### Belgium – FWO

| | |
|---|---|
| **Funding of industrial partners eligible?** | No |
| **Participation of industry required?** | No |
| **Maximum funding** | 200.000 EUR /1 project/ 3 years |
| **Eligible costs** | See national regulations |
| **Additional documents required** | No |
| **Other national restrictions** | See national regulations |

### Canada CIHR

| | |
|---|---|
| **Funding of industrial partners eligible?** | No |
| **Participation of industry required?** | No |
| **Maximum funding** | CIHR will contribute up to $200,000 per year per application, enough to fund approximately six (6) grants. |
| **Eligible costs** | Recipients should review the Use of Grant Funds section of the Tri-Agency (CIHR, NSERC and SSHRC) Financial Administration Guide for a complete listing and description of allowable costs and activities. |
| **Additional documents required** | Canadian applicants invited to submit a full application must complete a CIHR application and submit it using ResearchNet. The deadline for submission of this application is the same as the Full Application deadline to Joint Action Secretariat. The purpose of this additional application to CIHR is to provide CIHR with an Operating Budget for the project, with the amounts quoted in Canadian dollars, and a complete justification for funds requested. |
| **Other national restrictions** | The Nominated Principal Applicant (NPA) must be an independent Researcher.<br>The NPA must have an academic or research appointment at a CIHR eligible institution (See Institutional Eligibility Requirements for eligibility process and associated timelines. No indirect costs will be covered |

### Denmark DIF

| | |
|---|---|
| **Funding of industrial partners eligible?** | Yes |
| **Participation of industry required?** | No |
| **Maximum funding** | No |
| **Eligible costs** | See national guidelines: http://fivu.dk/en/research-and-innovation/councils-and-commissions/the-danish-council-for-strategic-research/dsf-filer/guidelines-transnational-calls-september-2013.pdf |
| **Additional documents required** | See national guidelines |
| **Other national restrictions** | See national guidelines |

### France ANR

| | |
|---|---|
| **Funding of industrial partners eligible?** | Yes |
| **Participation of industry required?** | No |
| **Maximum funding** | Minimum amount per partner: 15 000 €.<br>Maximum amount: 250 000 € |
| **Eligible costs** | Personnel, Consumables, Animals, Subcontracts (if costs<50% eligible costs), Equipment, Travel. See French Appendix for details (http://www.agence-nationale-recherche.fr/fileadmin/aap/2016/aap-jpiamr-2016-modalitefr.pdf) |
| **Additional documents required** | No |
| **Other national restrictions** | No |

### Germany BMBF/DLR

| | |
|---|---|
| **Funding of industrial partners eligible?** | Yes |
| **Participation of industry required?** | No |
| **Maximum funding** | No |
| **Eligible costs** | See national guidelines |
| **Additional documents required** | No |
| **Other national restrictions** | See national guidelines |

**Israel CSO-MOH**

| | |
|---|---|
| **Funding of industrial partners eligible?** | Only on their own funding |
| **Participation of industry required?** | No |
| **Maximum funding** | Up to 100,000 euros per project |
| **Eligible costs** | Personnel (students, technicians, applicants excluded); Animals, Materials and consumables; Travel (up to 10%); Institutional overhead 10%. No permanent equipment. |
| **Additional documents required** | Prior to submission, researchers will submit to CSO-MOH an abstract approved by their research authority including detailed budget distribution. No submission of abstract can lead to disqualification of the whole application, as well as the consortium. |
| **Other national restrictions** | Research will not be funded simultaneously by CSO-MOH on more than one grant (ERA-NET or national). Researchers can only apply for one grant from any ERA-NET funded by CSO-MOH or submit only one proposal for any single programme. Please see detailed instructions at www.health.gov.il/research-fund |

**Italy IT-MOH**

| | |
|---|---|
| **Funding of industrial partners eligible?** | Only Scientific Institutes for Research, Hospitalization and Health Care (Istituti di Ricovero e Cura a Carattere Scientifico pubblici e privati, IRCCS) are eligible.<br>No industrial partners are eligible. |
| **Participation of industry required?** | No |
| **Maximum funding** | Max 250.000 € per project |
| **Eligible costs** | Only costs generated during the lifetime of the project can be eligible. Personnel (only ad hoc contracts/consultants/fellowship, max 50% of the requested fund); travel costs and subsistence allowances (max 10% of the requested fund); equipment (rent/leasing only, no limit), consumables (no limit), dissemination of results (publications, meetings/workshops etc.- max 1% of the requested fund); data handling and analysis (no limit); overhead (maximum 10% of the requested fund). (All according to the national regulations).<br>Travel expenses and subsistence allowances associated with training activities only linked to the project |
| **Additional documents required** | The simultaneous participation in proposals submitted to different transnational research calls, funded by the Ministero della Salute, is not allowed to Italian Principal Investigators or other research team members.<br>In order to expedite the eligibility check process, the Ministry of Health will grant an eligibility clearance to the applicants prior to the submission of the pre-proposals. To this end, it is mandatory that the applicants fill out and return a pre-eligibility (Italy MOH mandatory pre-eligibility check form) check form trough IRCCS Scientific Directorate or Regional Office Health Research using WFR System 10 days before submitting their pre-proposals to the Joint Call Secretariat. It is strongly recommended that the form, completed and duly signed, is returned at least 10 working days before the pre-proposal submission deadline. Applicants will be sent a written notification of their eligibility status. |
| **Other national restrictions** | After the JPI-AMR JTC 2016 peer review has been completed and the final (scientific) ranking list has been performed and endorsed by the Call Steering Committee, the Ministry of Health will invite the principal investigators of the projects approved for funding to enter the formal national negotiations (according to national regulations). The funding of this projects are under the Ricerca Corrente IRCCS rules. |

## Latvia VIAA

| | |
|---|---|
| **Funding of industrial partners eligible?** | Yes, eligible<br>Enterprises entered into the Latvian Commercial registry, assumed they are eligible to do the specific research and are in possession of necessary resources in Latvia. Limitations of EU legislation apply (R651/2014) together with financial reporting and audit requirements |
| **Participation of industry required?** | No |
| **Maximum funding** | Per partner: 70.000 EUR/year, i.e. maximum grant per partner 210.000 EUR for a 3-year project. Can be increased by eventual top-up funding, ca 10% |
| **Eligible costs** | • Personnel incl. social tax (maximum rates apply)<br>• Consumables<br>• Animals<br>• Subcontracts (up to 25%) needs detailed justification, subject to approval. Includes all external services.<br>• Equipment (only depreciation costs)<br>• Replaceable un fully consumable during project elements of equipment e.g. electrodes fully<br>• Travel (according to travel plan)<br>• Indirect costs (up to 25% of direct costs exempt subcontracting)<br><br>Costs must be research and innovation costs, there is no support for other activities |
| **Additional documents required** | No |
| **Other national restrictions** | See Provisions of the Cabinet of Ministers: http://likumi.lv/ta/id/274671-atbalsta-pieskirsanas-kartiba-dalibai-starptautiskas-sadarbibas-programmas-petniecibas-un-tehnologiju-joma<br><br>They should be followed without any exception. All limits and conditions contained in the Provisions in relation to ERA-NET or ERA-NET Cofund are an eligibility criteria for funding |

## Netherlands ZON

| | |
|---|---|
| **Funding of industrial partners eligible?** | Please consult http://www.zonmw.nl/nl/subsidies/voorwaarden-en-financien/ or your national contact person |
| **Participation of industry required?** | No |
| **Maximum funding** | 1 Dutch participant in the consortium: max €300.000<br>2 Dutch participants in the consortium: max €450.000 (for the both of them together)<br>1 Dutch coordinator in the consortium: max €350.000<br>1 Dutch coordinator + 1 Dutch participant in the consortium: max €500.000 (for the both of them together) |
| **Eligible costs** | Please consult http://www.zonmw.nl/nl/subsidies/voorwaarden-en-financien/ or your national contact person |
| **Additional documents required** | Please consult http://www.zonmw.nl/nl/subsidies/voorwaarden-en-financien/ or your national contact person |
| **Other national restrictions** | Please consult http://www.zonmw.nl/nl/subsidies/voorwaarden-en-financien/ or your national contact person |

## Norway RCN

| | |
|---|---|
| **Funding of industrial partners eligible?** | Yes |
| **Participation of industry required?** | No |
| **Maximum funding** | 0,8 M€ for the total 3 year period |
| **Eligible costs** | 2 M€ for the total 3 year period |
| **Additional documents required** | No |
| **Other national restrictions** | See national guidelines. Please note that you can only be the Project manager for one project in this call. However you can be partner on several applications |

## Poland NCN

| | |
|---|---|
| **Funding of industrial partners eligible?** | Yes |
| **Participation of industry required?** | No |
| **Maximum funding** | €250 000 |
| **Eligible costs** | See Annex to NCN Council's Resolution on funding granted within calls for proposals for international research projects: https://ncn.gov.pl/sites/default/files/pliki/uchwaly-rady/2015/uchwala84_2015-zal1.pdf (p. 5-12).<br><br>Overhead costs must not exceed a maximum of 30% of the total eligible costs (excl. equipment) and may not be increased during the course of a research project. |
| **Additional documents required** | On the full proposal stage you will be requested to complete the following table: http://ncn.gov.pl/pliki/jpi-ec-abr_budget_table.xlsx. |
| **Other national restrictions** | Who can apply?<br>Any researcher, with a doctoral degree, employed at a Polish institution may act as a Principal Investigator.<br><br>Only proposals involving basic research (original experimental or theoretical research work undertaken primarily to acquire new knowledge of the underlying foundations of phenomena and observable facts) may be submitted in response to the call for proposals.<br><br>Applicants are obliged to adhere to the rules included in Annex to NCN Council's Resolution on funding granted within calls for proposals for international research projects: https://ncn.gov.pl/sites/default/files/pliki/uchwaly-rady/2015/uchwala84_2015-zal1.pdf |

## Portugal FCT

| | |
|---|---|
| **Funding of industrial partners eligible?** | Yes |
| **Participation of industry required?** | No |
| **Maximum funding** | Max 250.000 EUR /Project if the coordinator is a PT team; max 150.000 EUR /Project if PT team(s) is (are) only participant(s). See National Regulations: https://www.fct.pt/apoios/projectos/regulamento.phtml.en |
| **Eligible costs** | See National Regulations: https://www.fct.pt/apoios/projectos/regulamento.phtml.en |
| **Additional documents required** | Each Portuguese participant has to send to the Call National Contact Point a Statement of Commitment. See details in http://www.fct.pt/apoios/cooptrans/eranets/amr/index.phtml.en |
| **Other national restrictions** | See National Regulations: https://www.fct.pt/apoios/projectos/regulamento.phtml.en and check JPI-EC-AMR webpage in FCT's website http://www.fct.pt/apoios/cooptrans/eranets/amr/index.phtml.en |

## Romania ANCSI

| | |
|---|---|
| **Funding of industrial partners eligible?** | No |
| **Participation of industry required?** | No |
| **Maximum funding** | Up to 200.000 EUR/partner<br>Up to 250.000 EUR/coordinator |
| **Eligible costs** | See national guidelines http://uefiscdi.gov.ro/articole/4271/Dezbatere-publica-pachet-informatii-proiecte-ERA-NET-ERA-NET-Cofund.html |
| **Additional documents required** | No |
| **Other national restrictions** | See national guidelines http://uefiscdi.gov.ro/articole/4271/Dezbatere-publica-pachet-informatii-proiecte-ERA-NET-ERA-NET-Cofund.html |

## Spain ISCIII

| | |
|---|---|
| **Funding of industrial partners eligible?** | No |
| **Participation of industry required?** | No |
| **Maximum funding** | 500.000 € |
| **Eligible costs** | See http://eu-isciii.es/wp-content/uploads/2015/12/Eligibilidad_ISCIII_JPI-EC-AMR-1.pdf |
| **Additional documents required** | No |
| **Other national restrictions** | See http://eu-isciii.es/wp-content/uploads/2015/12/Eligibilidad_ISCIII_JPI-EC-AMR-1.pdf |

### Spain MINECO

| | |
|---|---|
| **Funding of industrial partners eligible?** | No. Although enterprises will not be funded through the APCIN Call, the Spanish industrial sector is much welcome to participate in the transnational consortia using their own funds. |
| **Participation of industry required?** | No |
| **Maximum funding** | See national guidelines: http://www.idi.mineco.gob.es/stfls/MICINN/Internacional/FICHEROS/Instrumentos_ERA/Anexo_Nacional_MINECO-AMR_2016.pdf |
| **Eligible costs** | - Personnel costs for temporary contracts (fellowships are not eligible).<br>- Current costs such as those incurred in purchasing small scientific and IT equipment, disposable materials, travelling expenses and other costs that can be properly justified as necessary to carry out the proposed activities.<br>- Indirect costs or clinical assays are not eligible for funding. |
| **Additional documents required** | No |

### Sweden FORMAS

| | |
|---|---|
| **Funding of industrial partners eligible?** | No |
| **Participation of industry required?** | No |
| **Maximum funding** | No |
| **Eligible costs** | The same as for applications for Formas project grants |
| **Additional documents required** | No |
| **Other national restrictions** | See national guidelines |

### Sweden SRC

| | |
|---|---|
| **Funding of industrial partners eligible?** | No |
| **Participation of industry required?** | No |
| **Maximum funding** | No |
| **Eligible costs** | The same as for applications for SRC project grants |
| **Additional documents required** | No |
| **Other national restrictions** | See national guidelines |

### Switzerland SNSF

| | |
|---|---|
| **Funding of industrial partners eligible?** | No |
| **Participation of industry required?** | No |
| **Maximum funding** | No |
| **Eligible costs** | See regular SNSF guidelines |
| **Additional documents required** | No |
| **Other national restrictions** | Projects must fit with the goals of the National Research Programme “Antimicrobial Resistance” (NRP 72): www.nrp72.ch |

**Turkey Tubitak**

| | |
|---|---|
| **Funding of industrial partners eligible?** | Yes |
| **Participation of industry required?** | No |
| **Maximum funding** | 120.000 TL/year with a maximum of 36 months |
| **Eligible costs** | Scholarships, materials, machines excluding infrastructures |
| **Additional documents required** | Electronic application print out,<br>If required, committee of ethics approval form,<br>Possession of rights declaration form,<br>For projects submitted previously, project proposal revision information form,<br>For non-Turkish citizens involved in the project as a project manager, researcher or advisor, official payment approval form,<br>Support letters (if applicable), Official permits (if required) |
| **Other national restrictions** | No |

**UK**

| | |
|---|---|
| **Funding of industrial partners eligible?** | No |
| **Participation of industry required?** | No |
| **Maximum funding** | Individual projects led by up to one UK group can request up to £300,000 per project and projects led by two groups can request up to £400,000 per project |
| **Eligible costs** | Follow MRC guidance |
| **Additional documents required** | No |
| **Other national restrictions** | UK Researchers must contact AMR@headoffice.mrc.ac.uk before submitting to ensure they are eligible to apply |

**Annex C: Guidelines for Consortium Agreement for Project Participants**

Each consortium should provide a Consortium Agreement (CA) signed by all participants before the start of the project to clarify the potential IPR matters (such as licensing in, licensing out, and patent and exploitation strategy). The CA must address (as a minimum), the following points:

- common start date and duration of the research project
- organisation and management of the project
- role and responsibilities of each partner, resources and funding
- confidentiality and publishing
- Intellectual Property Rights
- decision making within the consortium
- handling of internal disputes
- the liabilities of the research partners towards one another (including the handling of default of contract).

Any issues regarding funding are a bilateral matter between each project partner and the relevant funding organisation and should be excluded from the CA. The CA together with any other information required by national/regional regulations must be made available on request to the national funding agencies.